These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29443750)

  • 1. Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients.
    Liu DY; Wang ZG; Gao Y; Zhang HM; Zhang YX; Wang XJ; Peng D
    Medicine (Baltimore); 2018 Feb; 97(7):e9864. PubMed ID: 29443750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
    Luo J; Wang K; Liu D; Liang BM; Liu CT
    Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
    Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
    Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Poole P; Leung B; Black PN
    Cochrane Database Syst Rev; 2011 May; (5):CD002309. PubMed ID: 21563134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
    Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
    Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
    Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
    Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
    Lee SD; Hui DS; Mahayiddin AA; Roa CC; Kwa KH; Goehring UM; Bredenbröker D; Kuo HP
    Respirology; 2011 Nov; 16(8):1249-57. PubMed ID: 21848706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Roflumilast in Korean Patients with COPD.
    Lee JS; Hong YK; Park TS; Lee SW; Oh YM; Lee SD
    Yonsei Med J; 2016 Jul; 57(4):928-35. PubMed ID: 27189287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
    Porpodis K; Domvri K; Zarogoulidis P; Petridis D; Tsirgogianni K; Papaioannou A; Hatzizisi O; Kioumis I; Liaka A; Kikidaki V; Lampaki S; Organtzis J; Zarogoulidis K
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1123-8. PubMed ID: 26109853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
    Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
    Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD.
    Park TS; Kang J; Lee JS; Oh YM; Lee SD; Lee SW
    Int J Chron Obstruct Pulmon Dis; 2019; 14():871-879. PubMed ID: 31354255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
    Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
    Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.
    Kardos P; Mokros I; Sauer R; Vogelmeier CF
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1455-1468. PubMed ID: 29765213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
    Yan JH; Gu WJ; Pan L
    Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.
    Laube BL; Carson KA; Sharpless G; Paulin LM; Hansel NN
    J Aerosol Med Pulm Drug Deliv; 2019 Aug; 32(4):189-199. PubMed ID: 30964381
    [No Abstract]   [Full Text] [Related]  

  • 20. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
    Zheng J; Yang J; Zhou X; Zhao L; Hui F; Wang H; Bai C; Chen P; Li H; Kang J; Brose M; Richard F; Goehring UM; Zhong N
    Chest; 2014 Jan; 145(1):44-52. PubMed ID: 24135893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.